Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4230 Grade ≥3 subacute haematological toxicity with 177Lu-DOTATATE PRRT – Results from LUMEN study

Introduction: Bone marrow toxicity during peptide receptor radionuclide therapy (PRRT), results from radiation damage to haematopoietic tissue. Prospective comprehensive data on subacute haematological toxicity are scarce.

Conference:

Presenting Author: Mileva M

Authors: Mileva M, van Bogaert C, Ameye L, Flamen P, Karfis I,

Keywords: peptide receptor radionuclide therapy, GEP-NET, haematological toxicity,

#4116 A review of the Scottish national Peptide Receptor Radionuclide Therapy (PRRT) service with focus on patients with small bowel neuroendocrine tumors (SBNET) treated between April 2019 and March 2021

Introduction: Scottish National PRRT Service delivers 177Lu-Dotatate nationally at the Beatson West of Scotland Cancer Centre (BWoSCC). The NETTER-1 trial (Strosberg et al 2017) significantly changed the treatment and management of patients with gastroenteropancreatic NET (GEPNET). 177Lu-Dotatate demonstrated superiority in progression free survival (PFS) in patients with G1 and 2 midgut neuroendocrine tumors (NET). 177Lu-Dotatate 7.4 GBq 8 weekly gave 65% estimated progression free survival (PFS)at 20 months versus 10.8 % with 60mg octreotide intramuscularly 4 weekly (Strosberg et al 2017). Prior to this study everolimus was the most common 2nd line treatment for SBNET with a PFS of 14 months (Puscuddo et al 2017).

Conference:

Presenting Author:

Authors: Wotherspoon I, Charlick A, McIntosh D, Reed N,

Keywords: NETTER-1, Scottish PRRT Service,

#4015 Responses to Cabozantinib plus Atezolizumab in a wide population of advanced and progressive neuroendocrine neoplasms (NENs): A prospective multi-cohort basket phase II Trial (CABATEN / GETNE-T1914)

Introduction: Angiogenesis plays a key role in development and progression of NENs and synergism has been observed when combined with immune-checkpoint inhibitors in other tumors.

Conference:

Presenting Author: Molina-Cerrillo J

Authors: Molina-Cerrillo J, Grande E, Benavent M, Garcia-Carbonero R, Teule A,

Keywords: neuroendocrine neoplasm, Cabozantinib, Atezolizumab, CABATEN, prospective multi-cohort Basket Phase II Trial,

#3537 177Lu-DOTATATE (PRRT) in the treatment of patients with gastroenteropancreatic neuroendocrine tumors (GEPNETs) versus other tumors

Introduction: 177Lu-DOTATATE (PRRT) treatment is indicated in Spain in GEPNET but its activity in other somatostatin receptor-positive tumors is known.

Conference:

Presenting Author: Jimenez-Fonseca P

Authors: Jimenez-Fonseca P, Pubul V, Belló P, Riesco-Martinez M, Aller J,

Keywords: PRRT, NET, Somatostatin receptor-positive tumor, Survival,

#3173 Intestinal obstruction (IO) in patients receiving peptide receptor radionuclide therapy (PRRT) for gastro-enteropancreatic neuroendocrine tumors (GEP-NETs): Potential predictors and association with overall survival (OS)

Introduction: There are concerns for the risk of IO in patients with GEPNETs, especially in cases with peritoneal metastases or mesenteric vascular encasement.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Badawy M

Authors: Badawy M, Hobday T, Johnson G, Halfdanarson T, Young J,

Keywords: gastrointestinal NETs, PRRT (Lu-DOTATATE), intestinal obstruction, overall survival,